Caveat upfront: Human safety data is sparse. The pharmacology suggests NACET is a prodrug for NAC + a small amount of ethanol, both of which have well-characterized safety profiles, so the expected risk profile is "NAC-like with reduced sulfur smell." But chronic-toxicity data from large populations does not exist. Treat the side-effect profile below as inferred from mechanism + small case series + biohacker reports — not as established.

• Common (>10% users, by anecdote):

  • Mild GI upset / nausea — usually at higher doses on empty stomach. Less than parent NAC by anecdote.
  • Notably less sulfur smell / burp than NAC — probably the single most reproducible side-effect-profile difference.

• Less common (1-10%, by anecdote):

  • Headache (mild)
  • Loose stool (transient, dose-related)
  • Mild jitteriness in a small subset (possibly relating to glutamate normalization → cleaner cognition feel, possibly placebo)

• Rare-serious (<1% but mechanistically plausible — speculative because no large human series):

  • Hypotension at high doses combined with nitrate vasodilators (extrapolated from NAC interaction)
  • Theoretical bleeding-risk potentiation with anticoagulants (extrapolated from NAC's mild antiplatelet activity)
  • Allergic / rash reactions — case reports very rare

• Specific watch periods: None established. The biggest safety concern is unknown chronic toxicity at multi-year daily dosing, which has never been studied in humans. Parent NAC has 30+ years of human safety data at supplement doses; NACET has, generously, dozens of person-years of self-experimenter data and a few hundred patient-months of small-trial data. This is the single biggest argument against NACET as a chronic V4-replacement compound for a 20-year-old planning decades of daily use.

• Pregnancy / lactation: No data. Avoid in pregnancy/lactation by default.

• Long-term safety: Unknown. Animal chronic-toxicity studies are limited. The pharmacology suggests the in-vivo result is essentially "NAC + trace ethanol delivered intracellularly" which should have a similar long-term profile to NAC, but the inference is mechanistic, not empirical. This is a meaningful risk for a young user planning 60+ years of daily use.

• Quality / impurity risk from gray-market sourcing: Larger practical concern than pharmacologic risk. Without third-party COA, batch purity is unverified — unknown solvent residues, ester-purity (incomplete esterification leaves NAC + ethyl impurities), heavy metals, microbial contamination. Mitigated by sourcing from a vendor with published COA.

Upper safe intake: Unknown. By extrapolation from NAC, 1200 mg/day NACET should be very safe acutely; higher doses untested.